Tag: Biopharma M&A
-
Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion, gaining a precision autoantibody-degradation platform and multiple immunology programs.
-
LEO Pharma Bets Up to $435 Million on Oral Therapy for Rare Sunlight-Induced Pain
LEO Pharma is acquiring global rights to dersimelagon from Tanabe Pharma in a deal worth up to $435 million. The oral MC1R agonist has completed Phase 3 development in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) and has already been submitted to the FDA.
-
Jazz Bets $1.32 Billion on a Precision Therapy for Rare Epilepsy
Jazz is acquiring Actio Biosciences for up to $1.32 billion, gaining ABS-1230, a precision therapy targeting KCNT1-related epilepsy.
-
Tarsus Bets Up to $800 Million on a Deuterated Vitamin A Drug
Tarsus is acquiring Alkeus for up to $800 million, gaining gildeuretinol, a Phase 3 deuterated vitamin A therapy for Stargardt disease.